UNITED THERAPEUTICS Corp — fact timeline

UNITED THERAPEUTICS Corp reported the quarter ended March 31, 2026 results: revenue $781.5, net income $274.9, EPS $5.82.

“First Quarter 2026 Financial Results Key financial highlights include (dollars in millions, except per share data): Three Months Ended March 31, Dollar Change Percentage Change 2026 2025 Total revenues $ 781.5 $ 794.4 $ (12.9) (2) % Net income $ 274.9 $ 322.2 $ (47.3) (15) % Net income, per basic share $ 6.32 $ 7.18 $ (0.86) (12) % Net income, per diluted share $ 5.82 $ 6.63 $ (0.81) (12) %”

UNITED THERAPEUTICS Corp entered into Collared Accelerated Share Repurchase Agreement with Citibank, N.A. valued at $750,000,000 (effective 2026-03-09).

“Under the Collared ASR, which is being entered into pursuant to the Master Confirmation between the Company and Citi, dated August 1, 2025, the Company will receive an initial delivery of approximately 708,657 shares of Common Stock on March 11, 2026 representing approximately 50% of the total shares that would be repurchased under the Collared ASR (the Initial Delivery Amount ), measured based on the closing price of the Common Stock on March 9, 2026.”

UNITED THERAPEUTICS Corp entered into Uncollared Accelerated Share Repurchase Agreement with Citibank, N.A. valued at $750,000,000 (effective 2026-03-09).

“Under the Uncollared ASR, which is being entered into pursuant to the Master Confirmation between the Company and Citi, dated March 25, 2024, the Company will receive an initial delivery of approximately 992,120 shares of Common Stock on March 11, 2026 representing approximately 70% of the total shares that would be repurchased under the Uncollared ASR, measured based on the closing price of the Common Stock on March 9, 2026.”

UNITED THERAPEUTICS Corp: Amended and restated bylaws to implement cure process for director nomination deficiencies, remove language allowing board to require supermajority vote, and lower stockholder vote required to amend bylaws from 80% to majority of voting power (effective 2026-01-21).

“On January 21, 2026, the Board also approved amendments to, and the restatement of, the Company’s Tenth Amended and Restated Bylaws.”

UNITED THERAPEUTICS Corp incurred revolving credit of up to $2.5 billion with Wells Fargo Bank, National Association at an adjusted Term SOFR rate or a fluctuating base rate, in each case, plus an app maturing five years after the closing date of the Credit Agreement.

“National Association (“ Wells Fargo ”), as administrative agent and as a swingline lender. The Credit Agreement provides for an unsecured, revolving credit facility of up to $2.5 billion (which facility may, subject to obtaining commitments from existing or new lenders for such increase and subject to other condition, be increased by up to $750 million in the”

UNITED THERAPEUTICS Corp entered into Credit Agreement with Wells Fargo Bank, National Association valued at up to $1.2 billion (effective 2022-03-31).

“on March 31, 2022, United Therapeutics Corporation (the Company ) entered into a Credit Agreement (the Credit Agreement ) with certain of its subsidiaries party thereto, as guarantors, the lenders referred to therein, and Wells Fargo Bank, National Association ( Wells Fargo ), as administrative agent and as a swingline lender.”

UNITED THERAPEUTICS Corp entered into ASR Agreement with Citibank, N.A. valued at $1.0 billion (effective 2024-03-25).

“On March 25, 2024, the Company entered into an accelerated share repurchase agreement (the ASR Agreement ) with Citibank, N.A. ( Citi ) to repurchase approximately $1 billion of the Company’s common stock”

UNITED THERAPEUTICS Corp reported year ended December 31, 2023 results: revenue $2,327.5 million, net income $984.8 million, EPS $19.81 per diluted share.

“(Nasdaq: UTHR ), a public benefit corporation, today announced its financial results for the quarter and year ended December 31, 2023. Full year 2023 revenues rose to a record $2.33 billion, reflecting 20% growth over 2022. “Congratulations to the dedicated Unitherians who worked tirelessly to help us achieve our third straight quarter and second straight year of”

UNITED THERAPEUTICS Corp reported three months ended December 31, 2023 results: revenue $614.7 million, net income $217.1 million, EPS $4.36 per diluted share.

“Key financial highlights include (in millions, except per share data): Three Months Ended December 31, Year Ended December 31, 2023 2022 2023 2022 Total revenues $ 614.7 $ 491.5 $ 2,327.5 $ 1,936.3 Net income $ 217.1 $ 132.1 $ 984.8 $ 727.3 Net income, per basic share $ 4.62 $ 2.88 $ 21.04 $ 15.98 Net income, per diluted share $ 4.36 $ 2.67 $ 19.81 $ 15.00”

UNITED THERAPEUTICS Corp reported the quarter ended September 30, 2023 results: revenue $609.4 million, net income $267.6 million, EPS $5.38 per diluted share.

“United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, today announced its financial results for the quarter ended September 30, 2023. Total revenues in the third quarter of 2023 grew 18% year-over-year to $609.4 million, compared to $516.0 million in the third quarter of 2022.”

UNITED THERAPEUTICS Corp reported the quarter ended June 30, 2023 results: revenue $596.5 million, net income $259.2 million, EPS $5.24 per diluted share. Guidance reaffirmed.

“Total revenues in the second quarter of 2023 grew 28% year-over-year to $596.5 million, compared to $466.9 million in the second quarter of 2022.”

UNITED THERAPEUTICS Corp shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for 2023 at the 2023-06-26 meeting.

“5. Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for 2023: Votes for: 40,725,112 Votes against: 748,871 Abstentions: 10,672 Broker non-votes: —”

UNITED THERAPEUTICS Corp shareholders approved Approval of the amendment and restatement of the United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan at the 2023-06-26 meeting.

“4. Approval of the amendment and restatement of the United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan: Votes for: 34,925,060 Votes against: 5,085,389 Abstentions: 87,316 Broker non-votes: 1,386,890”

UNITED THERAPEUTICS Corp shareholders voted on Advisory vote on the frequency of future advisory votes on executive compensation at the 2023-06-26 meeting.

“3. An advisory vote on the frequency of future advisory votes on executive compensation: One year: 39,071,056 Two years: 4,467 Three years 956,691 Abstentions: 65,551 Broker non-votes: 1,386,890”

UNITED THERAPEUTICS Corp shareholders approved Advisory resolution to approve executive compensation at the 2023-06-26 meeting.

“2. An advisory resolution to approve executive compensation: Votes for: 38,688,651 Votes against: 1,188,503 Abstentions: 220,611 Broker non-votes: 1,386,890”

UNITED THERAPEUTICS Corp shareholders approved Election of directors at the 2023-06-26 meeting.

“1. Election of directors, each to serve a term of one year: Nominee Votes For Votes Against Abstentions Broker Non-Votes Christopher Causey 35,053,530 5,031,361 12,874 1,386,890 Raymond Dwek 36,922,017 3,160,178 15,570 1,386,890 Richard Giltner 38,428,288 1,653,830 15,647 1,386,890 Katherine Klein 38,338,087 1,747,250 12,428 1,386,890 Ray Kurzweil 37,519,403 2,565,464 12,898 1,386,890 Linda Maxwell 39,551,557 530,644 15,564 1,386,890 Nilda Mesa 37,815,938 2,261,956 19,871 1,386,890 Judy Olian 38,469,361 1,613,228 15,176 1,386,890 Christopher Patusky 36,100,963 3,983,909 12,893 1,386,890 Martine Rothblatt 38,170,992 1,905,182 21,591 1,386,890 Louis Sullivan 36,872,530 3,208,848 16,387 1,386,890 Tommy Thompson 33,785,847 6,295,860 16,058 1,386,890”

UNITED THERAPEUTICS Corp reported quarter ended March 31, 2023 results: revenue $506.9 million, net income $240.9 million, EPS $4.86 per diluted share.

“Total revenues in the first quarter of 2023 grew 10% year-over-year to $506.9 million, compared to $461.9 million in the first quarter of 2022.”

UNITED THERAPEUTICS Corp: Adopted Tenth Amended and Restated Bylaws with various amendments including enhanced stockholder proposal and director nomination procedures, adjourned meeting mechanics, proxy rules, and technical changes (effective 2023-04-20).

“On April 20, 2023, the Board of Directors (the “ Board ”) of United Therapeutics Corporation (the “ Company ”) approved and adopted the Company’s Tenth Amended and Restated Bylaws (as amended and restated, the “ Bylaws ”), which became effective the same day.”

UNITED THERAPEUTICS Corp amended Credit Agreement with Wells Fargo Bank, National Association, as administrative agent (effective 2023-03-31).

“Pursuant to Section 2.7 of the Credit Agreement, the maturity of the commitments and loans of each lender under the Credit Agreement has been extended by one year to March 31, 2028. The maturity extension became effective as of March 31, 2023.”

UNITED THERAPEUTICS Corp reported Year Ended December 31, 2022 results: revenue $ 1,936.3, net income $ 727.3, EPS $ 15.00.

“Key financial highlights include (in millions, except per share data): Three Months Ended December 31, Year Ended December 31, 2022 2021 2022 2021 Total revenues $ 491.5 $ 415.2 $ 1,936.3 $ 1,685.5 Net income $ 132.1 $ 112.2 $ 727.3 $ 475.8 Net income, per basic share $ 2.88 $ 2.49 $ 15.98 $ 10.60 Net income, per diluted share $ 2.67 $ 2.35 $ 15.00 $ 10.06”

UNITED THERAPEUTICS Corp reported Three Months Ended December 31, 2022 results: revenue $ 491.5, net income $ 132.1, EPS $ 2.67.

“Key financial highlights include (in millions, except per share data): Three Months Ended December 31, Year Ended December 31, 2022 2021 2022 2021 Total revenues $ 491.5 $ 415.2 $ 1,936.3 $ 1,685.5 Net income $ 132.1 $ 112.2 $ 727.3 $ 475.8 Net income, per basic share $ 2.88 $ 2.49 $ 15.98 $ 10.60 Net income, per diluted share $ 2.67 $ 2.35 $ 15.00 $ 10.06”

UNITED THERAPEUTICS Corp reported the quarter ended September 30, 2022 results: revenue $516.0 million, net income $239.3, EPS $4.91.

“benefit corporation, today announced its financial results for the quarter ended September 30, 2022. Total revenues in the third quarter of 2022 grew 16% year-over-year to $516.0 million, compared to $444.7 million in the third quarter of 2021. “We are thrilled to report the highest quarterly revenue in our history,” said Martine Rothblatt, Ph.D. , Chairperson”